Eli Lilly has exercised its option to progress a phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory diseases, triggering an undisclosed milestone payment to its partner Sitryx Therapeutics. Source: PM Live 3/11/2023